MedTrace Logo

Immunogenicity and Safety of One Dose of HPV Vaccine

NCT06345885 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-04-03

No results posted yet for this study

Summary

This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil

Conditions

  • Human Papillomavirus Vaccines

Interventions

BIOLOGICAL

HPV vaccine

Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months

Sponsors & Collaborators

  • Xiamen Innovax Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
14 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2024-01-17
Completion
2024-01-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06345885 on ClinicalTrials.gov